Drug Trial Radar · NCT06953986
A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
414
Planned (sponsor's estimate)
Start
Dec 20, 2025
Primary completion
Nov 20, 2026
Study completion Dec 12, 2027
Sponsor
- Lead sponsor
- Asian Institute of Gastroenterology, IndiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective • To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily. Secondary Objectives * To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events across treatment groups.
Conditions
- GERD
Interventions
VonoprazanDrug
Vonaprazon is potassium competitive acid blockers
Esomeprazole 40mgDrug
esomeprazole is a proton pump inhibitor as it prevents excess of gastric acid secretion in the stomach
Primary outcomes
What the sponsor says the trial is designed to measure.
- • Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).Time frame: 8 weeks
- Endoscopic healing of reflux esophagitis at 8 weeks (defined as resolution of LA grade B, C, or D esophagitis).Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asian Institute of Gastroenterology /Aig Hospitals
Hyderabad, Telangana, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.